Physician profile
Anthony Brown
NPI 1780631150
$7,760.31
in general payments reported to CMS, 2019-2025
45 companies · $870 in 2025
The $870 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $743 · 2021: $1,658 · 2022: $1,414 · 2023: $882 · 2024: $1,202 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $25.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,928.94 |
| Education | $25.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $818.56 | 2019-2025 | Veltassa |
| Bard Peripheral Vascular, INC. | $786.85 | 2019-2024 | Covera |
| Astrazeneca Pharmaceuticals LP | $628.96 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $537.15 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $470.60 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $461.84 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $417.07 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $372.10 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $309.10 | 2019-2025 | Auryxia, Vafseo |
| Amgen INC. | $286.22 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $269.82 | 2021-2025 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $268.30 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $219.75 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $214.45 | 2020-2025 | Injectafer |
| Genzyme Corporation | $196.32 | 2019-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.